tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2017-2-90-93tumors-348Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISВозможности применения альтернативных схем терапии сунитинибом у пациентов с метастатическим почечно-клеточным ракомPossibilities of using alternative schemes of sunitinib therapy in patients with metastatic renal cell carcinomaБяховА. В.ByakhovA. V.

врач-онколог, отделение клинической онкологии

MD, oncologist, Department of Clinical Oncology

ХисамовА. А.KhisamovA. A.

врач-хирург, отделение высокотехнологичной хирургии и хирургической эндоскопии

MD, surgeon, Department of High-Tech Surgery

arthisamov@mail.ruГБУЗ «Московский клинический научно-практический центр имени А.С. Логинова» (ГБУЗ МКНЦ ДЗМ), МоскваРоссияMoscow Clinical Scientific Center, MoscowRussian Federation201720072017029093Copyright © Бяхов А.В., Хисамов А.А., 20172017Бяхов А.В., Хисамов А.А.Byakhov A.V., Khisamov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/348

Сунитиниб является одним из основных препаратов для первой линии терапии светлоклеточного метастатического почечно-клеточного рака (мПКР). В настоящее время для достижения оптимального уровня концентрации препарата в плазме стандартной схемой терапии является режим 4/2 – 4 недели ежедневного приема 50 мг сунитиниба с последующим пере- рывом на 2 недели. Однако при такой схеме нередко встречаются побочные явления, что заставляет уменьшить дозировку препарата. За последние несколько лет накопились доказательства эффективности схемы 2/1 – 2 недели приема сунитиниба по 50 мг в день с последующим перерывом на неделю. Данная схема позволяет поддерживать необходимую концентрацию препарата в плазме, способствуя достоверному уменьшению частоты побочных явлений. В данной статье приведен обзор литературы, посвященный эффективности применения сунитиниба по схеме 2/1 у больных с мПКР. 

Sunitinib is one of the main drugs for the first line therapy for clear cell metastatic renal cell carcinoma (mRCC). At present, in order to achieve the optimal level of concentration of the drug in the plasma, the standard therapy regimen is 4/2 – 4 weeks of daily intake of 50 mg of sunitinib followed by a break for 2 weeks. However, with this scheme, side effects are often encountered. It makes necessary to reduce the dosage of the drug. Over the past few years, there is a growing evidence of the effectiveness of the scheme 2/1 – 2 weeks of taking sunitinib at 50 mg per day, followed by a break for a week. This scheme allows to maintain the necessary concentration of the drug in the plasma. This, in its turn, reduces, the rate of side effects. In this article, a review of the literature on the efficacy of sunitinib using scheme 2/1 in patients with mRCC is given. 

сунитинибметастатический почечно-клеточный рактаргетная терапияsunitinibmetastatic renal cell carcinomatargeted therapyReferencesHsieh J. J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y., Larkin J., Ficarra V. Renal cell carcinoma., Nat.Rev. Dis. Primers., 2017, Vol. 3, pp. 17009. doi: 10.1038/nrdp. 2017.9.Hsieh J. J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y., Larkin J., Ficarra V. Renal cell carcinoma., Nat.Rev. Dis. Primers., 2017, Vol. 3, pp. 17009. doi: 10.1038/nrdp. 2017.9.Ferlay J. et al. GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 1, 2013, GLOBOCAN http://globocan.iarc.fr (accessed on 4 Aug 2016).Ferlay J. et al. GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 1, 2013, GLOBOCAN http://globocan.iarc.fr (accessed on 4 Aug 2016).Torre L.A. et al. Global cancer statistics, 2012, CA Cancer J. Clin., 2015, Vol. 65, pp. 87–108.Torre L.A. et al. Global cancer statistics, 2012, CA Cancer J. Clin., 2015, Vol. 65, pp. 87–108.Global Burden of Disease Cancer Collaboration et al. The Global Burden of Cancer 2013, JAMA Oncol., 2015, Vol. 1, pp. 505–527.Global Burden of Disease Cancer Collaboration et al. The Global Burden of Cancer 2013, JAMA Oncol., 2015, Vol. 1, pp. 505–527.Каприн А.Д., Старинский В.В., Петрова Г.В., Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Москва, 2017. 250 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality), Moscow, 2017, 250 p. (In Russ.)].Каприн А.Д., Старинский В.В., Петрова Г.В., Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Москва, 2017. 250 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality), Moscow, 2017, 250 p. (In Russ.)].Motzer R. J., Hutson T. E., McCann L., Deen K., Choueiri T.K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib, N. Engl. J. Med., 2014, Vol. 370, pp. 1769–1770.Motzer R. J., Hutson T. E., McCann L., Deen K., Choueiri T.K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib, N. Engl. J. Med., 2014, Vol. 370, pp. 1769–1770.Schmid T.A., Gore M. E. Sunitinib in the treatment of metastatic renal cell carcinoma, Ther.Adv. Urol., 2016, Vol. 8, No. 6, pp. 348–371. Epub 2016 Aug 23.Schmid T.A., Gore M. E. Sunitinib in the treatment of metastatic renal cell carcinoma, Ther.Adv. Urol., 2016, Vol. 8, No. 6, pp. 348–371. Epub 2016 Aug 23.Bracarda S., Negrier S., Casper J., Porta C., Schmidinger M., Larkin J., Gross Goupil M., Escudier B. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma, Expert. Rev. Anticancer Ther., 2017, Vol. 17, No. 3, pp. 227–233. doi: 10.1080/14737140.2017.1276830. Epub 2017 Jan 3. Review.Bracarda S., Negrier S., Casper J., Porta C., Schmidinger M., Larkin J., Gross Goupil M., Escudier B. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma, Expert. Rev. Anticancer Ther., 2017, Vol. 17, No. 3, pp. 227–233. doi: 10.1080/14737140.2017.1276830. Epub 2017 Jan 3. Review.Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., Raymond E. J. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosinekinase inhibitor, in patients with cancer, Clin. Oncol., 2006, Vol. 24, No. 1, pp. 25–35. Epub 2005 Nov 28.Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., Raymond E. J. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosinekinase inhibitor, in patients with cancer, Clin. Oncol., 2006, Vol. 24, No. 1, pp. 25–35. Epub 2005 Nov 28.Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S. T., Chen I., Huang X., Figlin R.A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J. Clin. Oncol., 2009, Vol. 27, No. 22, pp. 3584–90. doi: 10.1200/JCO. 2008.20.1293. Epub 2009 Jun 1.Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S. T., Chen I., Huang X., Figlin R.A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J. Clin. Oncol., 2009, Vol. 27, No. 22, pp. 3584–90. doi: 10.1200/JCO. 2008.20.1293. Epub 2009 Jun 1.Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 2007, Vol. 356, No. 2, pp. 115–24.Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 2007, Vol. 356, No. 2, pp. 115–24.Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med., 2013, Vol. 369, No. 8, pp. 722–31. doi: 10.1056 / NEJMoa1303989.Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med., 2013, Vol. 369, No. 8, pp. 722–31. doi: 10.1056 / NEJMoa1303989.Houk B. E., Bello C. L., Poland B., Rosen L.S., Demetri G.D., Motzer R. J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol., 2010, Vol. 66, No. 2, pp. 357–71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5.Houk B. E., Bello C. L., Poland B., Rosen L.S., Demetri G.D., Motzer R. J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol., 2010, Vol. 66, No. 2, pp. 357–71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5.Britten C.D., Kabbinavar F., Hecht J.R. et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period, Cancer Chemother, Pharmacol., 2008, Vol. 61, pp. 515–524.Britten C.D., Kabbinavar F., Hecht J.R. et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period, Cancer Chemother, Pharmacol., 2008, Vol. 61, pp. 515–524.Atkinson B. J., Kalra S., Wang X. et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules, J. Urol., 2014, Vol. 191, pp. 611–618.Atkinson B. J., Kalra S., Wang X. et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules, J. Urol., 2014, Vol. 191, pp. 611–618.Bjarnason G.A., Khalil B., Hudson J.M. et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature, Urol. Oncol., 2014, Vol. 32, pp. 480–487.Bjarnason G.A., Khalil B., Hudson J.M. et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature, Urol. Oncol., 2014, Vol. 32, pp. 480–487.Bracarda S., Iacovelli R., Boni L. et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis, Ann. Oncol., 2015, Vol. 26, pp. 2107–2113.Bracarda S., Iacovelli R., Boni L. et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis, Ann. Oncol., 2015, Vol. 26, pp. 2107–2113.Kondo T., Takagi T., Kobayashi H. et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-weekoff in patients with metastatic renal cell carcinoma – comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off, Jpn. J. Clin. Oncol., 2014, Vol. 44, pp. 270–277.Kondo T., Takagi T., Kobayashi H. et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-weekoff in patients with metastatic renal cell carcinoma – comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off, Jpn. J. Clin. Oncol., 2014, Vol. 44, pp. 270–277.Najjar Y.G., Mittal K., Elson P. et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma, Eur. J. Cancer, 2014, Vol. 50, pp. 1084–1089.Najjar Y.G., Mittal K., Elson P. et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma, Eur. J. Cancer, 2014, Vol. 50, pp. 1084–1089.Lee J.L., Kim M.K., Park I. et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial, Ann. Oncol., 2015, Vol. 26, No. 11, pp. 2300–2305.Lee J.L., Kim M.K., Park I. et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial, Ann. Oncol., 2015, Vol. 26, No. 11, pp. 2300–2305.Neri B., Vannini A., Brugia M. et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients, Int. J. Urol., 2013, Vol. 20, pp. 478–483.Neri B., Vannini A., Brugia M. et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients, Int. J. Urol., 2013, Vol. 20, pp. 478–483.Yoo C., Kim J. E., Lee J. L. et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction, Jpn. J. Clin. Oncol., 2010, Vol. 40, pp. 980–985.Yoo C., Kim J. E., Lee J. L. et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction, Jpn. J. Clin. Oncol., 2010, Vol. 40, pp. 980–985.Population pharmacokinetic/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor, Clin. Pharmacokinet., 2016, Vol. 55, pp. 1251–1269.Population pharmacokinetic/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor, Clin. Pharmacokinet., 2016, Vol. 55, pp. 1251–1269.

The authors declare that there are no conflicts of interest present.